FDA publishes its list of unlawful compounded-drug marketing claims for telehealth companies
The FDA has spelled out five marketing claims it considers false or misleading when telehealth companies advertise compounded drugs, including compounded GLP-1s, giving consumers a checklist for spotting them [1].
The U.S. Food and Drug Administration has published a plain-language list of the advertising claims it treats as false or misleading when telehealth companies promote compounded drugs, specifically naming compounded glucagon-like peptide-1 receptor agonists (GLP-1s) [1]. The agency said such claims put patients at risk "as they cannot make an informed decision about their health based on false or misleading claims" and that the practice "also violates federal law" [1].
The five claims FDA flagged
The agency's page lists specific marketing moves it considers off-limits. First, using branding on a website that "falsely or misleadingly implies the telehealth company is the compounder" [1]. In other words, a sleek site that looks like it makes the medicine itself, when the drug actually comes from a separate pharmacy or outsourcing facility.
Second, describing a compounded drug as a generic version of an FDA-approved drug, or as the same as an FDA-approved drug [1]. FDA draws a sharp line here: "Generic drugs are approved by FDA prior to marketing, while a compounded drug is not approved by FDA" [1].
Third, claiming a compounded drug has been FDA-approved or otherwise evaluated for safety and effectiveness. The agency states that compounded drugs "are not reviewed by the agency for safety, effectiveness or quality prior to marketing" [1].
Fourth, describing a compounded drug as "clinically proven to produce the same result as the FDA-approved drug" [1].
Fifth, claiming a compounded drug is sourced from an FDA-approved or FDA-licensed pharmacy or outsourcing facility. FDA's response to that one is blunt: "FDA does not approve or license any facility" [1].
Enforcement is already underway
This is not purely advisory language. FDA says it "has issued warning letters to telehealth companies regarding concerns on false or misleading claims," and it points consumers and companies to its public warning letter database, suggesting the search term "telehealth" to find them [1]. The agency adds that it "remains vigilant in its oversight of promotional materials and will continue to take actions to help protect patients from false or misleading claims by telehealth companies" [1].
The source does not say how many warning letters have gone out, which companies received them, or what penalties followed. Those details are not in the material FDA published on this page.
Why it matters for patients
Compounded GLP-1 products have been widely advertised online, often alongside references to brand names like Ozempic, Wegovy, Mounjaro or Zepbound. FDA's list gives patients a concrete way to read those ads. If a site says its compounded semaglutide or tirzepatide is "FDA-approved," comes from an "FDA-approved pharmacy," is a "generic" of an approved drug, or is "clinically proven" to match the branded version, FDA's own page says those framings are false or misleading [1].
The practical core of it is the approval gap. An FDA-approved drug has been reviewed for safety, effectiveness and quality before it reaches the market. A compounded drug has not [1]. That difference doesn't appear on a label a patient can easily check, so marketing language is often the only signal people have, and FDA is saying some of that language cannot be trusted at face value.
The agency also highlights a structural point many patients may not realize: the telehealth company selling the prescription and the facility that actually compounds the drug can be two different businesses, and branding may blur that line [1]. Knowing who made a product matters if there is ever a quality problem or a recall.
What happens next
FDA has not published a deadline or a specific enforcement timeline on this page. What it has said is that it will keep monitoring promotional materials and keep taking action [1]. The warning letter database remains the public record of those actions, searchable under "telehealth" [1].
Anything beyond that, including how aggressively the agency will pursue individual companies or whether formal rulemaking follows, is not yet known from this source.
Sources
Semaglutides.org is for information only and is not medical advice. Always talk to a licensed healthcare provider about your own care. Some links to telehealth services are affiliate links, labeled where they appear.